结构性心脏病治疗赛道竞争加剧之际，爱德华生命科学Q2 交出 “增收不增利” 答卷，TAVR 负责人突然离职更添变数。财务表现：收入增长与利润承压并存爱德华生命科学最新发布的2025 年第二季度财报显示，公司在截至 6 月 30 日的季度中实现销售额15.3 亿美元，同比增长 11.9%，但净利润同比下降 7.7% 至 3.359 亿美元，每股收益 57 美分。这一 “增收不增利” 的现象反映出公司...
Source Link结构性心脏病治疗赛道竞争加剧之际，爱德华生命科学Q2 交出 “增收不增利” 答卷，TAVR 负责人突然离职更添变数。财务表现：收入增长与利润承压并存爱德华生命科学最新发布的2025 年第二季度财报显示，公司在截至 6 月 30 日的季度中实现销售额15.3 亿美元，同比增长 11.9%，但净利润同比下降 7.7% 至 3.359 亿美元，每股收益 57 美分。这一 “增收不增利” 的现象反映出公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.